Search results
AstraZeneca aims for $80 bln in total revenue by 2030
Reuters· 4 days ago, opens new tab aims to grow revenue by about 75% to $80 billion by 2030, it said on Tuesday,...
AstraZeneca shares rise as pharma group unveils 2030 revenue target By Investing.com
Investing.com· 4 days agoU.K.-listed shares in AstraZeneca (LON:AZN) rose in morning trading on Tuesday after the...
AstraZeneca to harness China's 'explosion' of innovation to boost cell therapy R&D
FierceBiotech· 4 days agoAstraZeneca’s growing presence in China will play a key role in the Big Pharma’s cell therapy...
...Biosciences Announces Global License and Option Agreement with AstraZeneca for Monoclonal...
The Woonsocket Call· 2 days agoNona is eligible to receive an additional US$10 million in potential near-term milestone payments and up to US...
AstraZeneca Admits Covishield Vaccine Can Cause Rare Side Effects, What Is TTS?
Homenewshere.com· 3 days agoAstraZeneca has acknowledged that its Covid vaccine, Covishield, can cause a rare side effect called...
AstraZeneca aims increase its annual revenue by 75% in its post-COVID era
Quartz· 4 days agoCambridge, U.K.-based pharmacuetical giant AstraZeneca announced an ambitious sales goal for the end of this decade, just as it pulls it COVID-19 vaccines off the shelves.
Pfizer wins cancer drug patent case against AstraZeneca
Pharmaceutical Technology via Yahoo Finance· 5 days agoThe US District Court for the District of Delaware has ordered AstraZeneca to pay $107.5m to Pfizer...
AstraZeneca pays $19M to Harbour BioMed's Nona for preclinical cancer antibodies
FierceBiotech· 2 days agoDays after AstraZeneca set out how new oncology drugs would help fuel its “bold” ambition to almost double its revenue by the end of the decade, the Big Pharma has further ...
AstraZeneca Aims for $80 Billion in Sales by 2030
Bloomberg· 4 days agoHave a confidential tip for our reporters? AstraZeneca Plc aims to almost double sales to $80 billion by 2030 as Chief Executive Officer Pascal Soriot...
AstraZeneca joins obesity biotech SixPeaks at basecamp with $80M for buyout option
FierceBiotech· 3 days agoThe obesity business is cutthroat these days. AstraZeneca is taking no chances on missing out on the...